Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | PHASE2 | NOT YET_RECRUITING | 120 | — | — | Oct 15, 2025 | Jan 15, 2030 | Sep 29, 2025 | 1 | Germany |
BORR defined as the proportion of patients with r/r DLBCL, HGBL and FL grade 3B who achieve a complete or partial remission as best response up to 12-months of study treatment according to the 2014 Lugano criteria.
| Arm | Type | Description |
|---|---|---|
| Loncastuximab Tesirine and Epcoritamab | EXPERIMENTAL | Combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma (DLBCL, HGBL or FL grade 3B) |
| Name | Type | Description |
|---|---|---|
| Loncastuximab Tesirine and Epcoritamab | DRUG | Combination therapy of loncastuximab tesirine and epcoritamab |
Inclusion Criteria: Disease: 1. Subjects with histologically confirmed relapsed/refractory DLBCL based on pathology report (WHO 2022 criteria) 1. DLBCL (de novo or transformed) 2. High-grade B-cell lymphoma with MYC and BCL2 rearrangements 3. High-grade B-cell lymphoma, not otherwise spe...